Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Treasury Shares: 2020-2025

Historic Treasury Shares for Adma Biologics (ADMA) over the last 4 years, with Sep 2025 value amounting to $1.3 million.

  • Adma Biologics' Treasury Shares was N/A to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year change of. This contributed to the annual value of $12.5 million for FY2023, which is 7.56% down from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Treasury Shares is $1.3 million, which was up 62.82% from $816,237 recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Treasury Shares peaked at $13.5 million during Q4 2022, and registered a low of $686,133 during Q2 2021.
  • In the last 3 years, Adma Biologics' Treasury Shares had a median value of $4.9 million in 2023 and averaged $5.1 million.
  • Over the last 5 years, Adma Biologics' Treasury Shares had its largest YoY gain of 591.18% in 2022, and its largest YoY loss of 7.60% in 2022.
  • Quarterly analysis of 5 years shows Adma Biologics' Treasury Shares stood at $4.5 million in 2021, then soared by 198.69% to $13.5 million in 2022, then fell by 7.56% to $12.5 million in 2023, then climbed by 20.91% to $5.9 million in 2024, then decreased by 0.67% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $816,237 for Q2 2025, and $5.9 million during Q1 2025.